16. Crow-Fukase syndrome Clinical trials / Disease details

Clinical trials : 13 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 4 - Drug target pathways : 75

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000018660	2015/08/17	17/08/2015	Japanese POEMS syndrome with thalidmaide trial for compassionate use	Japanese POEMS syndrome with thalidmaide trial for compassionate use - Japanese POEMS syndrome with thalidmaide trial for compassionate use (JPOST15)	Crow-Fukase(POEMS) syndrome	FPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4) Duration:until the approval of thalidomide for POEMT syndrome	Chiba University Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan
2	JPRN-JMA-IIA00084	22/03/2012	19/03/2012	Japanese POEMS Syndrome with Thalidomide Trial	Japanese POEMS Syndrome with Thalidomide Trial	Crow-Fukase (POEMS) syndrome	Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL.	J-POST Clinical Trial Office	Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University	Completed	>=20 YEARS	No Limit	BOTH	24	Phase 3	Japan
3	JPRN-JMA-IIA00046	13/09/2010	06/09/2010	Japanese POEMS Syndrome with Thalidomide Trial	Thalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety	Crow-Fukase (POEMS)syndrome	Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL.	J-POST Clinical Trial Office	Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University	Completed	>=20 YEARS	No Limit	BOTH	24	Phase 2-3	Japan